Independent · pepi.ninja
Peptide research and FDA compounding policy, without the noise.
We follow the U.S. Food and Drug Administration’s review of bulk drug substances under the Pharmacy Compounding Advisory Committee and maintain a curated reference index of peptides discussed in the published literature. We do not sell, distribute, or endorse the use of any substance.
- 50Peptides indexed
- 22Regulatory dispatches
- 100%Source-cited
Feature — Regulatory evidence
Research-only peptides: what the documented evidence actually shows
A citation-dense survey of identity testing, FDA enforcement records, Melanotan II case reports, and what the published harms literature has — and has not — investigated.
Sections
Three ways in.
Peptide reference index
A curated index of 50 peptides covered in the published literature, each with regulatory status, structural class, and source citations.
Browse peptides →Regulatory news & PCAC tracker
Coverage of FDA compounding policy, the Pharmacy Compounding Advisory Committee, and peptide-related regulatory developments.
Read regulatory →Methodology
What we cite, how we cite it, and the editorial standards behind every page on pepi.ninja.
Read methodology →Latest dispatches
From the tracker.
Subscribe
The pepi.ninja dispatch
Independent coverage of peptide research and FDA compounding policy. Updates on PCAC meetings, new published studies, and regulatory developments.